3/28
09:16 am
mbio
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases [Yahoo! Finance]
Low
Report
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases [Yahoo! Finance]
3/28
09:00 am
mbio
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Low
Report
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
3/11
04:27 pm
mbio
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
High
Report
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
3/11
04:05 pm
mbio
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Medium
Report
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
3/7
07:36 am
mbio
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma [Yahoo! Finance]
Medium
Report
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma [Yahoo! Finance]
3/7
07:30 am
mbio
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma
Medium
Report
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma
3/7
05:13 am
mbio
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial [Yahoo! Finance]
High
Report
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial [Yahoo! Finance]
3/7
05:00 am
mbio
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Medium
Report
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
2/21
06:11 am
mbio
Oncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc. [Yahoo! Finance]
Medium
Report
Oncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc. [Yahoo! Finance]